{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"3"}]}],"title":"TSH>ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"2"}]}],"title":"TSH > ULN WITH TSH <= ULN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}],"title":"TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN (A)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"}]}],"title":"TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"title":"WITH FT3/FT4 TEST MISSING"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}],"title":"TSH < LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"title":"TSH < LLN WITH TSH >= LLN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}],"title":"TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}],"title":"TSH < LLN WITH FT3/FT4 TEST MISSING"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"19"}],"units":"Participants"}],"groups":[{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1\n\nPomalidomide:\n\n4 mg po daily (Days 1-21) of each 28-day cycle\n\nDexamethasone:\n\nWeeks without daratumumab dosing 40 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects 75 years old 20 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects \\> 75 years old","id":"OG000","title":"Nivolumab + Daratumumab_Cohort A1"},{"description":"ND-Pd Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG001","title":"Nivolumab + Daratumumab_Cohort A2"},{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG002","title":"Nivolumab + Daratumumab_Cohort B1"},{"description":"D Monotherapy Regimen\n\nEach cycle is 28 days\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG003","title":"Nivolumab + Daratumumab_Cohort B2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in the nivo dara cohort with at Least One On-Treatment TSH Measurement","reportingStatus":"POSTED","timeFrame":"approximately up to 4 years","title":"Number of Participants With Clinical Laboratory Abnormalities by Worst Toxicity Grade in the Nivolumab + Daratumumab Cohort - Thyroid","type":"PRIMARY","unitOfMeasure":"Participants"}